Véronique Tack

Véronique Tack

Auto-generated profile, based on publicly available information

Véronique Tack

Department of Public Health and Primary Care, Biomedical Quality Assurance Research Unit, University of Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2015 in The Oncologist
Verified
Journal Article
Open access
PDF file
VTVéronique Tack
Véronique Tack
MLMarjolijn J.L. Ligtenberg
Marjolijn J.L. Ligtenberg
LTLien Tembuyser
Lien Tembuyser
NNNicola Normanno
Nicola Normanno
SBSara Vander Borght
Sara Vander Borght
EDElisabeth MC Dequeker
Elisabeth MC Dequeker
Background.: Regulations for the selection of patients with metastatic colorectal cancer for anti-EGFR treatment changed at the end of 2013. The set of mutations to be tested extended from KRAS codons 12 and 13 to KRAS and NRAS exons 2, 3, and 4. A European external quality assessment scheme monitored the performance of laboratories and evaluated the implementation of the new regulations. Materials and Methods.: The 131 participating laboratories received 10 samples of formalin-fixed paraffin-embedded material, including RAS (exon 2, 3, 4) and BRAF mutations. Mock clinical data were provided for three cases. Using their routine methods, laboratories determined the genotypes and submitted three written reports. Assessors scored the results according to predefined evaluation criteria. Results.: Half of the participants (49.3%) had completely implemented the new test requirements (codons 12, 13, 59, 61, 117, and 146 of KRAS and NRAS), and 96 laboratories (73.3%) made no genotype mistakes. Correct nomenclature, according to the Human Genome Variation Society, was used by 82 laboratories (62.6%). Conclusion.: Although regulations were effective for several months, many laboratories were not ready for full RAS testing in the context of anti-EGFR therapy. Nevertheless, in each participating country, there are laboratories that provide complete and correct testing. External quality assessments can be used to monitor implementation of new test regulations and to stimulate the laboratories to improve their testing procedures. Because the results of this program are available on the website of the European Society of Pathology, patients and clinicians can refer test samples to a reliable laboratory.

11 November 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LTLien Tembuyser
Lien Tembuyser
VTVéronique Tack
Véronique Tack
KZKaren Zwaenepoel
Karen Zwaenepoel
PPPatrick Pauwels
Patrick Pauwels
KMKeith Miller
Keith Miller
EDElisabeth MC Dequeker
Elisabeth MC Dequeker
Molecular profiling should be performed on all advanced non-small cell lung cancer with non-squamous histology to allow treatment selection. Currently, this should include EGFR mutation testing and testing for ALK rearrangements. ROS1 is another emerging target. ALK rearrangement status is a critical biomarker to predict response to tyrosine kinase inhibitors such as crizotinib. To promote high quality testing in non-small cell lung cancer, the European Society of Pathology has introduced an external quality assessment scheme. This article summarizes the results of the first two pilot rounds organized in 2012–2013. Tissue microarray slides consisting of cell-lines and resection specimens were distributed with the request for routine ALK testing using IHC or FISH. Participation in ALK FISH testing included the interpretation of four digital FISH images. Data from 173 different laboratories was obtained. Results demonstrate decreased error rates in the second round for both ALK FISH and ALK IHC, although the error rates were still high and the need for external quality assessment in laboratories performing ALK testing is evident. Error rates obtained by FISH were lower than by IHC. The lowest error rates were observed for the interpretation of digital FISH images. There was a large variety in FISH enumeration practices. Based on the results from this study, recommendations for the methodology, analysis, interpretation and result reporting were issued. External quality assessment is a crucial element to improve the quality of molecular testing.

1 July 2018 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
KDKelly Dufraing
Kelly Dufraing
GHGert De Hertogh
Gert De Hertogh
VTVéronique Tack
Véronique Tack
CKCleo Keppens
Cleo Keppens
EDElisabeth MC Dequeker
Elisabeth MC Dequeker
JKJ. Han van Krieken
J. Han van Krieken

1 November 2018 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
VTVéronique Tack
Véronique Tack
LSLien Spans
Lien Spans
Ed SchuuringEd Schuuring
Ed Schuuring
CKCleo Keppens
Cleo Keppens
UAUniveristy of Antwerp
Univeristy of Antwerp
EDElisabeth MC Dequeker
Elisabeth MC Dequeker

8 March 2021 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
CKCleo Keppens
Cleo Keppens
EBElke Boone
Elke Boone
PGPaula Gameiro
Paula Gameiro
VTVéronique Tack
Véronique Tack
EMElisabeth Moreau
Elisabeth Moreau
PGPatricia J. T. A. Groenen
Patricia J. T. A. Groenen
Clonality analysis of immunoglobulin (IG) or T-cell receptor (TR) gene rearrangements is routine practice to assist diagnosis of lymphoid malignancies. Participation in external quality assessment (EQA) aids laboratories in identifying systematic shortcomings. The aim of this study was to evaluate laboratories’ improvement in IG/TR analysis and interpretation during five EQA rounds between 2014 and 2018. Each year, participants received a total of five cases for IG and five cases for TR testing. Paper-based cases were included for analysis of the final molecular conclusion that should be interpreted based on the integration of the individual PCR results. Wet cases were distributed for analysis of their routine protocol as well as evaluation of the final molecular conclusion. In total, 94.9% (506/533) of wet tests and 97.9% (829/847) of paper tests were correctly analyzed for IG, and 96.8% (507/524) wet tests and 93.2% (765/821) paper tests were correctly analyzed for TR. Analysis scores significantly improved when laboratories participated to more EQA rounds (p=0.001). Overall performance was significantly lower (p=0.008) for non-EuroClonality laboratories (95% for IG and 93% for TR) compared to EuroClonality laboratories (99% for IG and 97% for TR). The difference was not related to the EQA scheme year, anatomic origin of the sample, or final clinical diagnosis. This evaluation showed that repeated EQA participation helps to reduce performance differences between laboratories (EuroClonality versus non-EuroClonality) and between sample types (paper versus wet). The difficulties in interpreting oligoclonal cases highlighted the need for continued education by meetings and EQA schemes.

23 September 2019 in Human Mutation
Verified
Journal Article
Open access
PDF file
CKCleo Keppens
Cleo Keppens
VTVéronique Tack
Véronique Tack
KDKelly Dufraing
Kelly Dufraing
EREtienne Rouleau
Etienne Rouleau
MLMarjolijn J.L. Ligtenberg
Marjolijn J.L. Ligtenberg
EDElisabeth MC Dequeker
Elisabeth MC Dequeker
A standardized nomenclature for reporting oncology biomarker variants is key to avoid misinterpretation of results and unambiguous registration in clinical databases. External quality assessment (EQA) schemes have revealed a need for more consistent nomenclature use in clinical genetics. We evaluated the propensity of EQA for improvement of compliance with Human Genome Variation Society (HGVS) recommendations for reporting of predictive somatic variants in lung and colorectal cancer. Variant entries between 2012 and 2018 were collected from written reports and electronic results sheets. In total, 4053 variants were assessed, of which 12.1% complied with HGVS recommendations. Compliance improved over time from 2.1% (2012) to 22.3% (2018), especially when laboratories participated in multiple EQA schemes. Compliance was better for next‐generation sequencing (20.9%) compared to targeted techniques (9.8%). In the 1792 reports, HGVS recommendations were met for 31.9% of reports, for 36.0% of non‐commercial, and 26.5% of commercial test methods. Compliance improved from 16.7% (2012) to 33.1% (2018), and after repeated EQA participation. EQA participation improves compliance with HGVS recommendations. The residual percentage of errors in the most recent schemes suggests that laboratories, companies, and EQA providers need to collaborate for additional improvement of harmonization in clinical test reporting.